Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication

Journal of Virology

Volumn 77, Issue 1, 2003, Pages 318-327

  Matsuoka Aizawa, Saori ^a   Sato, Hironori ^b   Hachiya, Atsuko ^a   Tsuchiya, Kiyoto ^a   Takebe, Yutaka ^b   Gatanaga, Hiroyuki ^a   Kimura, Satoshi ^a   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; LAMIVUDINE; NELFINAVIR; PROTEIN P55; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADAPTATION; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOLECULAR EVOLUTION; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE;

BLOTTING, WESTERN; DRUG RESISTANCE, VIRAL; GENES, GAG; HIV ENVELOPE PROTEIN GP41; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; NELFINAVIR; VIRUS REPLICATION;

EID: 0037213621     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.1.318-327.2003     Document Type: Article

References (29)

1. Aizawa, S., H. Gatanaga, S. Ida, A. Sakai, M. Tanaka, Y. Takahashi, Y. Hirahayashi, and S. Oka. 1999. Clinical benefits of resistance assay for HIV-specific protease inhihitors: When to check and in whom? AIDS 13:1278-1279.
2. Bleiher, G., M. Munoz, A. Ciuffi, P. Meylan, and A. Telenti. 2001. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J. Virol. 75:3291-3300.
3. Condra, J. H., C. J. Petropoulos, R. Ziermann, W. A. Schleif, M. Shivaprakash, E. A. Emini, M. Cornelissen, G. Kampinga, F. Zorgdrager, and J. Goudsmit. 2000. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J. Infect. Dis. 182:758-765.
4. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, H. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
5. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
6. Cotes, H. C., Z. L. Brumme, and P. R. Hartigan. 2001. Human immunodeficiency virus type I mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589-594.
7. Croteau, G., L. Doyon, D. Thibeault, G. McKerche, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type I variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096.
8. Dauher, D. S., R. Ziermann, N. Parkin, D. J. Maly, S. Mabrus, J. L. Harris, J. A. Ellman, C. Petropoulos, and C. S. Craik. 2002. Altered substrate specificity of drug-resistant human immunodeficiency virus type I protease. J. Virol. 76:1359-1368.
9. Deeks, S. G., T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. K. Hallerstein, and G. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
10. Gatanaga, H., S. Aizawa, Y. Kikuchi, N. Tachikawa, I. Genka, S. Yoshizawa, Y. Yamamoto, A. Yasuoka, and S. Oka. 1999. Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors. AIDS Res. Hum. Retrovir. 15:1493-1498.
11. Gatanaga, H., Y. Suzuki, H. Tsang, K. Yoshimura, M. F. Kavlick, K. Nagashima, R. J. Gorelick, S. Mardy, C. Tang, M. F. Summers, and H. Mitsuya. 2002. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-I resistance against protease inhibitors. J. Biol. Chem. 277:5952-5961.
12. + cell clone 1-10 (MAGIC-5). Antimicrob. Agents Chemother. 45:495-501.
13. Katz, R. A., and A. M. Skalka. 1994. The retroviral enzymes. Annu. Rev. Biochem. 63:133-173.
14. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. A. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
15. + T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-I. J. Virol. 69:3712-3720.
16. Mammano, F., C. Petit, and F. Clavel. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 72:7632-7637.
17. Mammano, F., V. Trouplin, V. Zennou, and F. Clavel. 2000. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug. J. Virol. 74:8524-8531.
18. Martinez-Picado, J., A. V. Savara, L. Sutton, and R. T. D'Aquila. 1999. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73:3744-3752.
19. Miller, V., C. Sahin, K. Hertogs, S. Bloor, J. Martinez-Picado, R. D'Aquila, B. Larder, T. Lutz, P. Gute, E. Weidmann, H. Rahenau, A. Phillips, and S. Staszewski. 2000. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14:2857-2867.
20. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
21. Rohinson, L. H., R. E. Myers, B. W. Snowden, M. Tisdale, and E. D. Blair. 2000. HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays. AIDS Res. Hum. Retrovir. 16:1149-1156.
22. Sato, H., J. Orenstein, D. Dimitrov, and M. Martin. 1992. Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology 186;712-724.
23. Sato, H., T. Shiino, N. Kodaka, K. Taniguchi, Y. Tomita, K. Kato, T. Miyakuni, and Y. Takebe. 1999. Evolution and biological characterization of human immunodeficiency virus type 1 subtype E gp120 V3 sequences following horizontal and vertical virus transmission in a single family. J. Virol. 73:3551-3559.
24. Sato, H., Y. Tomita, K. Shibamura, T. Shiino, T. Miyakuni, and Y. Takebe. 2000. Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies. J. Virol. 74:5357-5362.
25. Sato, H., Y. Tomita, K. Ebisawa, A. Hachiya, K. Shibamura, T. Shiino, R. Yang, M. Tatsumi, K. Gushi, H. Umeyama, S. Oka, Y. Takebe, and Y. Nagai. 2001. Augmentation of HIV-1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase. J. Virol. 75:5604-5613.
26. Wiegers, K., G. Rutter, H. Kottler, U. Tessmer, H. Hohenberg, and H. G. Krausslich. 1998. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J. Virol. 72:2846-2854.
27. Willey, R. L., D. H. Smith, L. A. Lasky, T. S. Theodore, P. L. Earl, B. Moss, D. J. Capon, and M. A. Martin. 1988. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62:139-147.
28. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306.
29. Zhang, Y. M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.